-
3 days ago | 
ascopost.com | Chase Doyle
Providing a brief, 90-day course of preoperative endocrine therapy to older women with early-stage, estrogen receptor–positive, invasive breast cancer may significantly alter both patient preferences and physician recommendations regarding adjuvant radiation therapy, according to data presented during the 2025 American Society of Breast Surgeons (ASBrS) Annual Meeting.1 Primary results from the phase II multicenter POWER trial showed that this preoperative window allowed patients to gauge...
-
1 week ago | 
ascopost.com | Chase Doyle
Ropeginterferon alfa-2b demonstrated superior efficacy and safety compared with anagrelide as second-line therapy for patients with essential thrombocythemia (ET) who were intolerant or resistant to hydroxyurea, according to data from the phase III SURPASS-ET trial presented at the European Hematology Association (EHA) 2025 Congress (Abstract S102).
-
1 week ago | 
ascopost.com | Chase Doyle
Adding tafasitamab-cxix, an anti-CD19 monoclonal antibody, to lenalidomide and rituximab significantly prolonged progression-free survival in patients with relapsed or refractory follicular lymphoma, according to data presented at the European Hematology Association (EHA) 2025 Congress (Abstract S230).
-
2 weeks ago | 
ascopost.com | Chase Doyle
Maintenance treatment with the alkylating agent lurbinectedin plus the monoclonal antibody atezolizumab significantly improved both progression-free survival and overall survival compared with atezolizumab alone in patients with extensive-stage small cell lung cancer (SCLC), according to data presented at a press briefing ahead of the 2025 ASCO Annual Meeting.1 At a median follow-up of 15 months, median progression-free survival more than doubled from 2.1 months with atezolizumab alone to 5.4...
-
1 month ago | 
ascopost.com | Chase Doyle
Zongertinib, an investigational oral, HER2-selective, EGFR-sparing tyrosine kinase inhibitor, elicited durable responses and demonstrated clinical benefit in patients with advanced, previously treated, HER2-mutant non–small cell lung cancer (NSCLC), according to data presented by John V.
-
1 month ago | 
ascopost.com | Chase Doyle
For postmenopausal women with hormone receptor–positive ductal carcinoma in situ (DCIS) treated with breast-conserving surgery, whole-breast irradiation, and adjuvant endocrine therapy, reexcision to achieve wider surgical margins (≥ 1 mm or ≥ 2 mm) may not be necessary, according to data presented at the 2025 American Society of Breast Surgeons (ASBrS) Annual Meeting.1 Analysis of the large NRG Oncology/NSABP B-35 trial found that differences in 10-year ipsilateral breast tumor recurrence...
-
1 month ago | 
ascopost.com | Caroline Helwick |Chase Doyle
Thousands of forward-looking research studies defined the 2025 American Association for Cancer Research (AACR) Annual Meeting. Here, aside from our fuller coverage of key presentations in The ASCO Post, we offer a snapshot of a few additional abstracts that may be of interest to cancer researchers and clinicians.
-
2 months ago | 
ascopost.com | Chase Doyle
Postmastectomy radiation therapy may be significantly shortened for many patients planning breast reconstruction, according to data from a large phase III trial (RT CHARM, Alliance A221505).1 Investigators reported that hypofractionated (short-course) radiation therapy was found to be noninferior to conventional fractionation in patients with breast cancer who underwent breast reconstruction after mastectomy.
-
2 months ago | 
ascopost.com | Chase Doyle
Proton beam therapy and intensity-modulated radiation therapy (IMRT) were found to offer equivalent quality-of-life outcomes for patients with localized prostate cancer, according to data from the PARTIQoL trial. This phase III trial showed no measurable differences between the two approaches in terms of bowel function, urinary symptoms, or sexual function.
-
2 months ago | 
ascopost.com | Chase Doyle
Current standard chemoradiation therapy remains the most effective treatment for selected patients with human papillomavirus (HPV)-positive oropharyngeal cancer, based on the results of the NRG-HN005 trial. Researchers have halted this large, randomized phase II/III trial after patients in the control arm reached an unprecedented 2-year progression-free survival rate of 98%, setting a new benchmark for treatment efficacy in early-stage, HPV-associated oropharyngeal cancer.
